Fundz

Kasvu Therapeutics has raised €30 million in a Series A financing round led by Hadean Ventures. The funding will advance its novel TrkB potentiator into clinical development targeting neuropsychiatric disorders.

PRIVATESep 24, 2026

Amount Raised

€30 Million

Round Type

Series A

HelsinkiBiotechnologyHealth CareTherapeutics

Investors

TesiInnovestor Life Science FundFinnish Drug Discovery CenterStephen IndustriesNordic Science InvestmentsHelsinki University FundsHadean Ventures

Description

Kasvu Therapeutics, a company focused on developing neuroplastogens, announced its €30 million Series A financing round. The round was led by Hadean Ventures with participation from various investors including Tesi and Innovestor Life Science Fund. The funds will aid in advancing its lead candidate KTX-0141 through clinical development. Clinical trials are anticipated to start in the latter half of 2027.

Who to call at Kasvu Therapeutics, and when

A new round usually means Kasvu Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Kasvu Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Kasvu Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Kasvu Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Kasvu Therapeutics

Location

Helsinki, Uusimaa, Finland

About

Kasvu Therapeutics is developing a new generation of neuroplastogens for neuropsychiatric and neurodegenerative disorders. The company focuses on a novel class of small-molecule potentiators designed to enhance neuroplasticity pathways without inducing hallucinogenic effects. Their lead candidate, KTX-0141, selectively amplifies BDNF signaling to potentially treat major depressive disorder and other mental health conditions. Kasvu aims to provide rapid-acting and long-lasting treatment options for patients.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Kasvu Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Kasvu Therapeutics's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

Kasvu Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.